Come Meet Us at The 26th International Molecular Med TRI-CON Conference

Molecular Med Tri-Con - March 11-14, 2019 - San Francisco, CA

Biotech Support Group will exhibit at the annual Molecular Med TRI-CON Conference, March 11-14, 2019 in San Francisco, CA. The conference is a premier event in the Molecular Medicine and Diagnostics field, and highlights the most recent advancements in Digital Health, Liquid Biopsy and Immuno-oncology. The expected attendance of 3,700 brings together senior level executives, directors and scientists within pharmaceutical companies and oncology-focused institutions and organizations.

Featured at Booth 337, will be a patent pending cancer biomarker panel – Stroma Liquid Biopsy™, commercialized through partnerships, and consumable sample prep products for blood proteome enrichment. Simply click on the image to learn more about our featured products.

Looking for liquid biopsy protein biomarkers? Find out how to enrich your blood proteome better. Why waste time and money using antibodies for depletion? Find out how we enrich your proteome better. Stroma Liquid Biopsy White Paper - February 2019 Does Hemoglobin Interfere with your Analysis? Find out how to enrich your blood proteome better.

In addition, there will be two technical poster reports:

The first is entitled " New Cancer Therapeutic Strategies are Proposed Based on Evidence from Stroma Liquid Biopsy™ Biomarkers", co-authored with collaborators from Vanderbilt University.


Tumors are more than simply a collection of immortalized cells as the supporting microenvironments or stroma also contributes to pathogenesis. Because of this, tumor characterization cannot be fully characterized solely through the analyses of the tumor cell genome – the current emphasis of liquid biopsy platforms. So because tumors are more than just a mass of proliferating cells, cancer progression must take into consideration the influence of the multiple cell types and networks of proteins dynamically interacting in active tumorigenesis. These are not simply passive bystanders. The unique significance of the Stroma Liquid Biopsy™ pan-cancer profile is that dysregulation was categorically intertwined with the most rudimentary needs of cancer: space, nutrients and immune evasion. Moreover, the changes within the 13 biomarker panel all occur within an interdependent network of cascading proteolytic events. Because proteolysis is irreversible, all species of life have evolved molecular regulatory systems to control aberrancies. The most distinguished is a protease inhibitory family of regulators known as SERPINs. Although SERPINs circulate in a variety of functional on/off sub-forms, conventionally they are observed and reported in aggregate (i.e., ELISA). As a result, their influence on disease is missed. Using assays that directly assess SERPIN function, rather than antigen presentation, we now have evidence that there is an imbalance of functional SERPIN sub-forms in the cancer population relative to that of a normal population. Consequently, new insights will be extracted into the opportunistic mechanisms that drive cancer pathogenesis and metastatic dissemination, and we advance how those might be unwound therapeutically to improve survival.

The second is entitled " AlbuVoid™ Enrichment & Antibody Depletion – Tackling the Challenges of Serum Proteomics Part II", co-authored with collaborators from the Rutgers Proteomics Center.


Proteomic workflows that support serum proteomics can be especially challenging for two reasons: 1) the presence of highly abundant proteins, Albumin alone accounts for about 50% of the total protein mass, and 2) a particularly proteolytic resistant sample type due the large concentration of antibodies present. Many proteomic enrichment strategies employ the use of immuno-affinity depletion to remove one or more high abundance proteins. Some common limitations of immuno-affinity however are high costs, regeneration requirements which may result in a diminished and inconsistent performance, as well as a required marriage of species to antibody. Because of these limitations, researchers need ways to enrich differently. We have previously reported a variety of tools that can bias towards or against select sub-proteomes of serum without the use of immuno-affinity. Now we report the serum proteome bias characteristics of AlbuVoid™ & NuGel™ Protein A, alone or in serial combination, using LC-MS reporting metrics. Products and digest conditions produce different proteome qualitative and quantitative windows of observation. For biomarker discovery, we solicit the value for enrichment of categorical sub-proteomes to provide mechanistic insight into disease pathologies. For this, a knowledgebase of over 1000 serum proteins is now available to help proteomic researchers choose the best available products and methods for their particular needs.

For more information, please contact Matt Kuruc,, 732-274-2866